Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Trial Profile

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2018

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms BOSS PD
  • Most Recent Events

    • 06 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 26 Jan 2018 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
    • 26 Jan 2018 Planned primary completion date changed from 30 Jun 2020 to 31 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top